Evra Patch (Norelgestromin/Ethinyl Estradiol)

Name: Evra Patch
Brand: Searchlight Pharma
SKU: 2535
Availability: InStock

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Evra Patch 21 Days (3 Patches per Pack)

Manufacturer: Searchlight Pharma

Country: Canada

Dosage: 200mcg/24hrs - 35mcg/24hrs

Qty-Price (USD):

Generic Equivalent of Evra Patch

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

There is no generic product of Evra Patch.

Evra Patch Information

Evra Patch at CanadaPharmacyOnline.com

The manufacturer of the Evra Patch available at this pharmacy is Searchlight Pharma Inc. (Montréal, Québec, Canada). The Evra Patch was originally developed and marketed in Canada and internationally by Janssen-Ortho Inc. (a division of Johnson & Johnson). Following Janssen’s restructuring of its contraceptive portfolio, Canadian marketing rights were transferred to Searchlight Pharma Inc., which now holds the license. The Evra Patch is the first transdermal contraceptive patch to receive Health Canada approval (December 2003). It remains the only contraceptive patch approved in Canada.

There is currently no generic equivalent available for the Evra Patch at this pharmacy.

Dosage:

The Evra Patch is a transdermal extended-release system available in one strength:
• Evra Patch: Each patch contains 6.00 mg norelgestromin and 0.60 mg ethinyl estradiol, releasing approximately 200 mcg norelgestromin and 35 mcg ethinyl estradiol per 24 hours through the skin.

Each pack contains 3 patches, supplying 21 active patch-wearing days. The Evra Patch is applied once weekly for three consecutive weeks (21 days), followed by a one-week (7-day) patch-free interval. One complete cycle is 28 days. Only one patch is to be worn at a time.

Usage:

The Evra Patch (norelgestromin and ethinyl estradiol transdermal system) is indicated for the prevention of pregnancy in women of reproductive age who choose a non-oral method of hormonal contraception. It is an alternative for women who prefer the convenience of a once-weekly dosing schedule over a daily oral contraceptive pill. Clinical trials have demonstrated that adherence to the weekly patch-changing schedule is better than adherence to daily oral contraceptive dosing.

The Evra Patch may be less effective in women weighing more than 90 kg (approximately 198 lbs) or more and may be contraindicated in women with a BMI greater than 30 kg/m2 due to the increased risk of blood clots. Women above this weight should discuss alternative contraceptive options with their doctor. The Evra Patch does not protect against HIV (AIDS) or other sexually transmitted infections (STIs). Use of latex or polyurethane condoms in combination with the Evra Patch is advised for protection against STIs.

Mechanism of Action
The Evra Patch prevents pregnancy through the same hormonal mechanisms as combined oral contraceptives (COCs), using norelgestromin (a progestin) and ethinyl estradiol (an estrogen) delivered continuously through the skin directly into the bloodstream, bypassing the digestive system and liver.

The three primary mechanisms of action are:
• Suppression of ovulation (primary mechanism): The sustained, steady-state levels of norelgestromin and ethinyl estradiol suppress the pituitary release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This prevents follicular development and the mid-cycle LH surge that triggers ovulation. When a patch is first applied, a steady state of hormone delivery is reached within approximately 48 hours.
• Cervical mucus thickening: The progestin component increases the viscosity of cervical mucus, forming a barrier that significantly impedes sperm penetration and transport through the cervical canal.
• Endometrial modification: The combined hormones alter the endometrium (uterine lining), reducing its thickness and receptivity, thereby decreasing the likelihood of implantation.

Absorption rates are equivalent across approved application sites (buttock, abdomen, upper outer arm, upper torso). They are unaffected by exercise, exposure to hot or cold water (bathing, swimming, sauna), or humid conditions. While the patch delivers a 35 mcg daily dose, it results in higher total estrogen exposure (AUC) compared to oral pills, which may slightly increase the risk of certain side effects like blood clots.

Apply the Evra Patch exactly as your doctor prescribes, following the instructions on the product packaging.

The information below summarizes some, but not all, potential side effects, risks, and interactions. Before starting the Evra Patch, it is essential to discuss all possible side effects, risks, and interactions with your doctor or pharmacist.

Side Effects:

The information below outlines potential side effects of the Evra Patch (norelgestromin/ethinyl estradiol). It is not an exhaustive list, and individual reactions can vary.

Common side effects: These are common side effects of the Evra Patch; other side effects are possible. Contact your doctor promptly if any side effects are persistent, worsening, or concerning, or if you experience any other concerning symptoms.
• Application site reactions: skin redness, irritation, rash, or itching at the patch site
• Breakthrough bleeding or spotting between periods, especially in the first few cycles
• Breast discomfort, pain, or tenderness
• Changes in menstrual flow (lighter periods or missed withdrawal bleeding)
• Decreased sex drive (libido)
• Dysmenorrhoea (painful periods)
• Fluid retention or bloating
• Headache

Serious Side Effects: Seek immediate medical attention or call emergency services if you experience any of the following symptoms:
• Anaphylaxis: Hives, rash, swelling of the face, lips, tongue, or throat, or difficulty breathing.
• Change in migraine pattern: A new migraine with focal neurological aura (visual disturbances, unilateral numbness, weakness), or a significant increase in migraine frequency or severity. Discontinue the Evra Patch immediately.
• Gallbladder disease
• High blood pressure
• Liver problems: Yellowing of the eyes or skin (jaundice), dark urine, or severe upper abdominal pain.
• Severe depression: New or worsening severe depression or suicidal thoughts, discontinue and seek mental health support.
• Signs of blood clots: Pain, swelling, redness, or warmth in a leg (DVT), sudden shortness of breath, chest pain, or coughing up blood (pulmonary embolism).

Contraindications:

The following is not an exhaustive list of contraindications. Before starting the Evra Patch, it is crucial to discuss all your medical conditions, past and present, and all medications you are taking with your doctor or pharmacist.

Do not use the Evra Patch/norelgestromin/ethinyl estradiol if: • A current or past history of deep vein thrombosis (DVT), pulmonary embolism (PE), or other thromboembolic disorders.
• A current or past history of migraine with focal neurological aura symptoms.
• A history of cholestatic jaundice of pregnancy or jaundice caused by prior hormonal contraceptive use.
• A history of myocardial infarction (heart attack), coronary artery disease, cerebrovascular accident (stroke), transient ischaemic attack (TIA), or angina pectoris.
• Allergies: You have a known hypersensitivity to norelgestromin, ethinyl estradiol, or any ingredient in the patch.
• Breast cancer or hormone-sensitive malignancy
• Certain HCV combination drug regimens (Contraindicated): The Evra Patch must not be used with the hepatitis C virus combination drug regimen, such as ombitasvir/paritaprevir/ritonavir, with or without dasabuvir
• Diabetes mellitus with vascular involvement.
• Major surgery or prolonged immobilization: Discontinue the Evra Patch at least 4 weeks before major surgery or prolonged immobilization, due to an increased risk of VTE. Restart no sooner than 2 weeks after full mobilization.
• Obesity with multiple cardiovascular risk factors
• Severe dyslipoproteinaemia.
• Severe hypertension
• Undiagnosed abnormal vaginal bleeding.

Tell your doctor about all of your medical conditions, past and present, before starting the Evra Patch. This is crucial as certain conditions affect the patch’s safety.
• A history of depression or mood disorders
• Gallbladder disease or a family history of gallstones
• Hyperlipidemia or hypertriglyceridemia
• Inflammatory bowel disease
• Renal impairment

Drug Interactions:

Before applying the Evra Patch, discuss all potential risks and interactions with your doctor or pharmacist. For complete, up-to-date information, please refer to the product monograph at https://pdf.hres.ca/dpd_pm/00046284.PDF.

Provide your doctor with a complete list of all your medications, including prescriptions, over-the-counter (OTC) drugs, vitamins, herbal supplements, recreational drugs, and any significant dietary changes, as these may interact with the Evra Patch. The Evra Patch may interact with other medicines, including but not limited to:
• Antiretroviral drugs (HIV medications): ritonavir, nelfinavir, nevirapine, and efavirenz can significantly decrease estrogen and progestin levels, reducing contraceptive efficacy. Use an additional non-hormonal contraceptive method.
• Atorvastatin and rosuvastatin: Co-administration may increase ethinyl estradiol blood concentration.
• Cyclosporine, prednisolone, and theophylline: Ethinyl estradiol may inhibit the metabolism of these drugs, increasing their plasma concentrations and potential for toxicity.
• CYP3A4 enzyme inducers: such as rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, oxcarbazepine, topiramate, felbamate, primidone, bosentan, and griseofulvin. Use a non-hormonal backup method of contraception during and for 28 days after stopping any enzyme-inducing drug.
• Hepatitis C combination drug regimens (Contraindicated): The Evra Patch must be discontinued before starting the HCV regimen of ombitasvir/paritaprevir/ritonavir with or without dasabuvir due to a significant risk of ALT elevation. The patch may be restarted approximately 2 weeks after completing this HCV therapy.
• Vitamin C and Tylenol: May increase plasma ethinyl estradiol concentrations through inhibition of its conjugation, if taken regularly in high doses.
• Warfarin and other anticoagulants: Estrogen-containing hormonal contraceptives may interact with anticoagulant therapy.

Pregnancy and Breastfeeding:

The Evra Patch is not approved for use during pregnancy. Discontinue immediately if pregnancy is confirmed or suspected. If withdrawal bleeding does not occur during the patch-free week and the patch has been applied correctly, pregnancy is not necessarily indicated. However, if two consecutive withdrawal bleeds are missed, rule out pregnancy before continuing with the medication. For breastfeeding women, estrogen-containing contraceptives such as the Evra Patch are generally not recommended. Hormones may pass into breast milk, reducing milk quantity and quality.

Use in Children:

The Evra Patch is not indicated for use before menarche. Safety and efficacy have been established in women aged 18 to 45. Use in adolescents aged 18 and younger is at the discretion of a healthcare provider, provided menarche has been reached. It is not intended for use by males.

Frequently Asked Questions about the Evra Patch at Canada Pharmacy Online

Why is the Evra Patch more affordable in Canada than in the United States?

Prescription drug prices, including the Evra Patch, are generally lower in Canada than in the U.S. due to a combination of factors, primarily government price regulations, differing market dynamics, and other economic considerations. In Canada, provincial and federal governments negotiate drug prices with pharmaceutical companies, which often results in lower prices than in the U.S., where market forces play a more significant role. For more information, see the FAQs on Prescription Drug Importation from the Kaiser Family Foundation (KFF): https://www.kff.org/health-costs/issue-brief/faqs-on-prescription-drug-importation/

How much is the shipping?

Our shipping fee is a flat rate of $10.00 per order. Our pharmacy is dedicated to offering you the lowest prices on high-quality products.

How do I place an order with your pharmacy?

Ordering from us is very simple. You can purchase online or call Customer Service at 1.866.920.3784; for more information or to learn about the ordering process, visit our How to Order page.

Is there a limit on how many Evra Patches I can order at once?

CanadaPharmacyOnline.com can dispense up to a three-month supply of the Evra Patch per prescription from your doctor.

Can I buy the Evra Patch from you over the counter?

No, the Evra Patch requires a valid prescription from your doctor. We do not sell this product without a valid prescription.

Do you ship to the United States?

Yes, we do. It usually takes between 7 and 18 business days to receive your order from our pharmacy.

Is there a generic for the Evra Patch?

There is currently no generic equivalent available for the Evra Patch at this pharmacy.

Blog Post:

Alesse Birth Control Pill Review

Latest News:

Birth Control Patch With Lower Estrogen Dose Effective in Phase 3 Trial (Study published May 15, 2025)

Similar Drugs in the category of Birth Control Pills:

Nextstellis Ortho Tri Cyclen Lo Yasmin Diane 35 Nuvaring Vaginal Ring

The information on this page is sourced from independent third parties contracted by CanadaPharmacyOnline. While we cannot guarantee its medical accuracy, we strongly recommend consulting a healthcare professional for personalized advice regarding medications or medical conditions.

Reviews From Real Customers